dr. yu on combining pembrolizumab and olaparib in mcrpc
Published 5 years ago • 197 plays • Length 1:14
Download video MP4
Download video MP3
Similar videos
-
2:18
evan yu, md, regarding combination pembrolizumab and olaparib in mcrpc
-
1:15
dr. yu on rationale for the keynote-365 study in mcrpc
-
2:38
keynote-365 cohort a: pembrolizumab plus olaparib in docetaxel-pretreated patients with mcrpc
-
1:10
dr. yu on the future of castration-sensitive prostate cancer
-
2:58
evan yu, md, elaborates on the results from keynote 365 in mcrpc
-
1:29
evan yu, md, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer
-
1:23
nicholas vogelzang, md, fasco, facp, regarding combination pembrolizumab and olaparib in mcrpc
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer
-
3:18
keynote-199: an update on pembrolizumab for mcrpc
-
1:54
dr. yu on the significance of the protect study in prostate cancer
-
4:30
profound: olaparib for hrr mcrpc
-
1:30
dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
2:10
dr. gulley discusses a phase ii study of olaparib and durvalumab in mcrpc
-
1:06
dr. yu on comorbidities and therapy choice in prostate cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
1:00
dr. yu on moderate hypofractionation in prostate cancer
-
1:13
dr. yu on the role of pet imaging in prostate cancer
-
1:42
dr. yu compares treatment options for prostate cancer
Clip.africa.com - Privacy-policy